Description
This volume thoroughly covers HIV-1 antiretrovirals currently in clinical use, together with their advantages and limitations. HIV-1 inhibitor resistance is discussed in detail, and critical assessments as to what will be required of future antiretrovirals in order to halt viral replication, reduce viral resistance, and alter the state of viral latency are presented. Experts at the forefront of HIV-1 research provide overviews of approaches from the fields of virology, chemical biology and structural biology for obtaining small molecule inhibitors that target viral regulatory and structural components at multiple points in the viral lifecycle. The individual chapters will appeal to scientists and clinicians alike. HIV Therapy Looking Towards the Future David Looney, Ariel Ma, and Scott Johns Computational challenges of structure-based approaches applied to HIV Stefano Forli and Arthur J. Olson Nucleocapsid Protein: A Desirable Target For Future Therapies Against HIV-1 Mattia Mori, Lesia Kovalenko, Sbastien Lyonnais, Danny Antaki, Bruce E. Torbett, Maurizio Botta, Gilles Mirambeau, and Yves Mly HIV-1 integrase multimerization as a therapeutic target Lei Feng, Ross Larue, Jacques J. Kessl, and Mamuka Kvaratskhelia Targeting HIV transcription: The quest for a functional cure Guillaume Mousseau, Sonia Mediouni, and Susana T. Valente Targeting the HIV RNA Genome: High-Hanging Fruit Only Needs a Longer Ladder Stuart F.J. Le Grice HIV-1 Gag: An Emerging Target for Antiretroviral Therapy Philip R. Tedbury and Eric O. Freed The Triple Threat of HIV-1 Protease Inhibitors Marc Potempa, Sook-Kyung Lee, Richard Wolfenden, and Ronald Swanstrom Illustrations of the HIV Life Cycle David S. Goodsell
